MX2010004373A - Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos. - Google Patents

Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.

Info

Publication number
MX2010004373A
MX2010004373A MX2010004373A MX2010004373A MX2010004373A MX 2010004373 A MX2010004373 A MX 2010004373A MX 2010004373 A MX2010004373 A MX 2010004373A MX 2010004373 A MX2010004373 A MX 2010004373A MX 2010004373 A MX2010004373 A MX 2010004373A
Authority
MX
Mexico
Prior art keywords
vehicles
aqueous water
drug delivery
miscible materials
pharmaceutical composition
Prior art date
Application number
MX2010004373A
Other languages
English (en)
Inventor
Brian R Rohrs
Martin J Coffey
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2010004373A publication Critical patent/MX2010004373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica que incluye al menos un componente farmacéutico que tiene una baja solubilidad acuosa y por lo menos un material miscible en agua no acuoso. Esta composición farmacéutica es útil para proporcionar una cantidad terapéuticamente significativa del componente farmacéutico en un tejido objetivo. La composición farmacéutica es particularmente adecuada para su administración a o en un ambiente ocular para tratar o controlar una enfermedad, trastorno o afección ocular.
MX2010004373A 2007-11-01 2008-10-17 Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos. MX2010004373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98440507P 2007-11-01 2007-11-01
PCT/US2008/080267 WO2009058585A2 (en) 2007-11-01 2008-10-17 Non-aqueous water-miscible materials as vehicles for drug delivery

Publications (1)

Publication Number Publication Date
MX2010004373A true MX2010004373A (es) 2010-05-05

Family

ID=40328704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004373A MX2010004373A (es) 2007-11-01 2008-10-17 Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.

Country Status (10)

Country Link
US (1) US20090118262A1 (es)
EP (1) EP2219601A2 (es)
JP (1) JP2011502989A (es)
KR (1) KR20100072333A (es)
CN (1) CN101842080A (es)
AU (1) AU2008319074A1 (es)
BR (1) BRPI0818483A2 (es)
CA (1) CA2702761A1 (es)
MX (1) MX2010004373A (es)
WO (1) WO2009058585A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012074019A1 (ja) * 2010-11-30 2012-06-07 株式会社ブリヂストン 精製セルロース繊維、繊維－ゴム複合体及びタイヤ
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2013046059A2 (en) * 2011-09-27 2013-04-04 Sykora Robert C Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose
FR2988297B1 (fr) * 2012-03-22 2014-03-28 Thea Lab Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
EP2853623A4 (en) * 2012-05-21 2016-01-20 Bridgestone Corp CORD, RUBBER CORD ASSOCIATED STRUCTURE AND TIRES
US9125805B2 (en) * 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
GR1008168B (el) * 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Παρεντερικο σκευασμα αντιβακτηριακου παραγοντα φθοριοκινολονης και μεθοδος για την παρασκευη αυτου
TW201536347A (zh) * 2013-07-11 2015-10-01 參天製藥股份有限公司 含有環孢素ａ之水性眼科用組成物
US20180177879A1 (en) * 2015-06-05 2018-06-28 Maruho Co., Ltd External preparation for transdermal administration
WO2021221074A1 (ja) * 2020-04-27 2021-11-04 千寿製薬株式会社 ブリモニジンを含有する液体製剤
US11523987B2 (en) * 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767788A (en) * 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
JPS6143114A (ja) * 1984-08-03 1986-03-01 Takeda Chem Ind Ltd 虹彩・毛様体疾患治療用眼局所投与剤
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
JP3072340B2 (ja) * 1991-10-21 2000-07-31 ポーラ化成工業株式会社 水性目薬及びその製造法
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
US5336487A (en) * 1993-03-05 1994-08-09 Refojo Miguel F Method of treating eye disorders with silicon/fluorosilicone copolymer oil
US5480914A (en) * 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
JP2003055201A (ja) * 2001-08-13 2003-02-26 Lion Corp ビタミンａ類含有可溶化組成物及びビタミンａ類の安定化方法
WO2004009056A1 (en) * 2002-07-23 2004-01-29 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
EP1773350B1 (en) * 2004-07-12 2013-05-29 Allergan, Inc. Opthalmic compositions for treating ophthalmic conditions
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP1848431B1 (en) * 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Liquid formulations for treatment of diseases or conditions
JP2009516687A (ja) * 2005-11-21 2009-04-23 シェーリング−プラウ・リミテッド ブプレノルフィンを含む薬学的組成物
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
JP2008120764A (ja) * 2006-11-15 2008-05-29 Nippon Tenganyaku Kenkyusho:Kk プロスタグランジン水性点眼剤

Also Published As

Publication number Publication date
AU2008319074A1 (en) 2009-05-07
CA2702761A1 (en) 2009-05-07
US20090118262A1 (en) 2009-05-07
CN101842080A (zh) 2010-09-22
BRPI0818483A2 (pt) 2015-04-14
WO2009058585A3 (en) 2009-11-26
JP2011502989A (ja) 2011-01-27
WO2009058585A2 (en) 2009-05-07
KR20100072333A (ko) 2010-06-30
EP2219601A2 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
MX2010004373A (es) Materiales miscibles en agua no acuosos como vehiculos para suministro de farmacos.
WO2009109927A3 (en) Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
WO2010009111A3 (en) A drug depot implantable within a synovial joint
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
MX2010004366A (es) Materiales inmiscibles en agua como vehiculos para suministro de farmacos.
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
WO2009137827A3 (en) Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
WO2008137758A3 (en) Amino acid lipids and uses thereof
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
CL2008003545A1 (es) Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo.
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
EP1765452A4 (en) SUPPLY SYSTEM

Legal Events

Date Code Title Description
FA Abandonment or withdrawal